44. Monkarsh SP, et al. Positional isomers of monopegylated interferon α-2a: isolation, characterization, and biological activity.
Anal. Biochem. 1997, 247:434-40.
45. Lee H, Park TG. A novel method for identifying PEGylation sites of protein using biotinylated PEG derivatives. J. Pharm.
Sci. 2003, 92:97-103.
46. Fee CJ. Size-exclusion reaction chromatography (SERC): A new technique for protein PEGylation. Biotechnol. Bioeng. 2003,
47. Greenwald RB, et al. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 2003, 55:217-50.
48. Graham ML. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 2003, 55:1293-1302.
49. Parkinson C, Scarlett JA, Trainer PJ. Pegvisomant in the treatment of acromegaly. Adv. Drug Deliv. Rev. 2003, 55:1303-14.
50. Bory C, et al. Comparison of red cell transfusion and polyethylene glycol-modified adenosine deaminase therapy in an adenosine
deaminase-deficient child: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool. Pediatr. Res. 1990, 28:127-30.
51. Conover CD, et al. The ability of polyethylene glycol conjugated bovine hemoglobin (PEG-Hb) to adequately deliver oxygen
in both exchange transfusion and top-loaded rat models. Artif. Cells Blood Substit. Immobil. Biotechnol. 1999, 27:93-107.
52. Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov.
Today 2003, 8:259-66.
53. Francis GE, et al. Polyethylene glycol modification: relevance of improved methodology to tumour targeting. J. Drug Target
54. Kitamura K, et al. Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem.
Biophys. Res. Commun. 1990, 171:1387-94.
55. Leong SR, et al. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications
using site-specific pegylation. Cytokine 2001, 16:106-119.
56. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 2002, 54:531-45.
57. Francis GE, et al. PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation
of coupling techniques. Int. J. Hematol. 1998, 68:1-18.
58. O'Riordan CR, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody
in vitro and in vivo. Hum. Gene Ther. 1999, 10:1349-58.
59. Crawford J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat. Rev. 2002, 28:7-11.
60. Teske E, et al. Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma. Eur.
J. Cancer 1990, 26:891-95.
61. Tan Y, et al. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy. Protein Expr. Purif. 1998,
62. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs.
63. Belcheva N, et al. Synthesis and biological activity of polyethylene glycol-mouse nerve growth factor conjugate. Bioconjug.
Chem. 1999, 10:932-37.
64. Kim TH, Lee H, Park TG. Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable
PLGA microspheres. Biomaterials 2002, 23:2311-17.
65. Hokom MM, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated
with carboplatin and irradiation in mice. Blood 1995, 86:4486-92.
66. Snider J, et al. Characterization of the heterogeneity of polyethylene glycol-modified superoxide dismutase by chromatographic
and electrophoretic techniques. J. Chromatogr. 1992, 599:141-55.
67. Tsutsumi Y, et al. PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb. Haemost. 1997,
68. Katre NV, Knauf MJ, Laird WJ. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its
potency in the murine Meth A sarcoma model. Proc. Natl. Acad. Sci U. S. A 1987, 84:1487-91.
69. Murakami Y, Hoshi R, Hirata A. Borate buffer dramatically enhances the activity of poly(ethylene)glycol-a-chymotripsin
complex catalitically active in anhydrous isooctane. Biotechnol. Lett. 2001, 23:125-29.
70. Hu RG, et al. Bioactivities of ricin retained and its immunoreactivity to anti-ricin polyclonal antibodies alleviated
through pegylation. Int. J. Biochem. Cell Biol. 2002, 34:396-402.